Testing a drug to reduce swelling in donor lungs before transplant
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests whether blocking a protein called IL-1 with a single dose of anakinra can reduce swelling in the donor lung during the transplant process. If you are having a lung transplant and your donor lung is treated with a machine that keeps it alive outside the body (EVLP), you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You are scheduled to receive a lung transplant
- The donor lung will be treated with ex vivo lung perfusion (EVLP) before transplant
- You have not taken any IL-1 blocking medication before
- You do not have conditions that would make the transplant riskier, such as being highly sensitized, needing a multi-organ transplant, or having a prior lung transplant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests whether blocking a specific inflammation signal (TNF-alpha) can help prevent or improve kidney problems and early graft (new lung) dysfunction after a lung transplant at Northwestern. You might be eligible if you’re scheduled for that transplant and are willing to go through study consent and follow-up.
This trial tests a drug called tocilizumab (brand name Actemra) to see if it helps prevent rejection after lung transplantation. Tocilizumab targets part of the immune system that may otherwise attack the new lungs.
This trial tests an immune-suppressing medicine to stop a serious complication called primary graft dysfunction that can happen soon after a lung transplant. It may help people who are already on the transplant waiting list and plan to receive a standard anti-rejection drug regimen.
This study tests whether a drug called emapalumab can help lung transplant recipients whose transplanted lungs are showing signs of rejection. The drug targets a specific immune protein (interferon gamma) that appears to drive this type of rejection.
This trial tests whether a drug called anakinra can prevent blood clots (immunothrombosis) after a pancreas transplant. If you are scheduled for a pancreas transplant (alone or with a kidney) at Nantes University Hospital, you may be able to join.
This Phase 3 trial tests ARINA-1 to slow or prevent worsening lung transplant scarring in the breathing tubes (bronchiolitis obliterans). It may help people who are showing early decline in lung function but are not yet at advanced disease.
Hear when a new Lung Transplant Recipient trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.